Evidence map›Paper›PMID 40699368›Full record

ArticleSurgery today2026

Long-term survival outcome after surgical resection of pulmonary neuroendocrine tumors.

Eisuke Goto, Keiju Aokage, Kotaro Nomura, Makoto Tada, Yutaro Koike, Tetsuro Taki, Tomohiro Miyoshi, Kenta Tane, Joji Samejima, Kenji Suzuki and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Eisuke GotoDepartment of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Keiju AokageDepartment of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. kaokage1213@gmail.com.ORCID http://orcid.org/0000-0003-3193-9646
Kotaro NomuraDepartment of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Makoto TadaDepartment of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Yutaro KoikeDepartment of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Tetsuro TakiDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Tomohiro MiyoshiDepartment of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Kenta TaneDepartment of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Joji SamejimaDepartment of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Kenji SuzukiDepartment of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Genichiro IshiiDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Masahiro TsuboiDepartment of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSurgery is the standard treatment for early-stage pulmonary neuroendocrine tumors (NETs); however, long-term prognostic data are limited. This study aimed to establish the long-term outcomes of surgically resected pulmonary NETs.

methodsThis study included 263 patients who underwent pulmonary resection between January, 1997 and December, 2019: 89 with small cell lung carcinoma (SCLC), 120 with large cell neuroendocrine carcinoma (LCNEC), 14 with atypical carcinoid (AC), and 40 with typical carcinoid (TC). We analyzed clinicopathological characteristics and long-term prognosis.

resultsThe 5-year relapse-free survival (RFS) rates were 38.7%, 54.2%, 62.3%, and 85.0%, and the 10-year RFS rates were 24.5%, 39.8%, 20.8%, and 76.4% for SCLC, LCNEC, AC, and TC, respectively. All deaths from TC occurred more than 5 years after surgery, whereas three of the four deaths from AC occurred after this period. Most patients with high-grade NETs had relapses within 3 years after surgery, whereas patients with AC had relapses not only in the early phase but also in the late phase.

conclusionsThe long-term prognosis of AC is comparable to that of high-grade NETs, suggesting that its biological characteristics might be more closely related to high-grade NETs than to TC.

Indexed as

Lung NeoplasmsNeuroendocrine TumorsPneumonectomyAdultAgedAged, 80 and overCarcinoid TumorCarcinoma, Large CellFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisSmall Cell Lung CarcinomaSurvival RateAtypical carcinoidCarcinoidPulmonary neuroendocrine tumor

Identifiers

PMID40699368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.